STOCK TITAN

Millennium Group and Israel Englander Disclose 3.06M TXG Shares (2.7%)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported beneficial ownership of 3,060,859 shares of 10x Genomics, Inc. Class A common stock, representing 2.7% of the class. The cover pages show shared voting power of 2,979,280 shares and shared dispositive power of 3,060,859, with no sole voting or dispositive power reported by the filing parties.

The statement is submitted on a Schedule 13G/A and includes a joint filing agreement among the reporting persons. The filing also states that the shares are held by entities subject to voting control and investment discretion by Millennium Management and related managers, and disclaims that this alone constitutes admission of beneficial ownership.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Reported 3.06M shares (2.7%) by Millennium-related filers; size is sub-5% and likely limited near-term market impact.

The filing discloses an aggregate holding of 3,060,859 shares representing 2.7% of 10x Genomics' Class A stock, with reported shared voting power of 2,979,280 and shared dispositive power of 3,060,859. As a Schedule 13G/A disclosure for holders of 5% or less, this is a transparency filing rather than an indicator of control. For market models, a 2.7% passive stake is typically immaterial to corporate control and valuation modeling unless accompanied by further strategic moves.

TL;DR: The joint filing and shared control metrics show coordinated reporting; the filing explicitly disclaims admission of beneficial ownership.

The document includes a Joint Filing Agreement (Exhibit I) among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander and reports collective holdings with shared voting and dispositive powers. The filing language cautions that the allocation of voting and investment discretion should not be construed as an admission of beneficial ownership, which is a standard governance disclosure clarifying responsibilities among affiliated managers and principals.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/11/2025
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/11/2025
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:08/11/2025
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 11, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What percentage of 10x Genomics (TXG) does that holding represent?

2.7% of the Class A common stock as reported in the filing.

What voting and dispositive powers are disclosed for this position?

Shared voting power: 2,979,280; Shared dispositive power: 3,060,859; Sole powers: 0.

Who filed the Schedule 13G/A for TXG?

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are the reporting persons.

Does the filing include a joint filing agreement?

Yes. Exhibit I is a Joint Filing Agreement among the reporting persons.

Does the filing assert that the reporting persons admit beneficial ownership?

No. The filing states the allocation of control and discretion should not be construed as an admission of beneficial ownership.